Latour J G, Léger-Gauthier C, Daoust-Fiorilli J
Pathology. 1984 Oct;16(4):411-7. doi: 10.3109/00313028409084732.
Pathogenesis of the microthrombi produced during intravascular coagulation was investigated in rabbits given intravenous infusions of thrombin or adenosine diphosphate (ADP). Thrombin, at a dosage producing a fibrinogen consumption of 70% within 4 h (1 unit/kg/min), failed to produce extrapulmonary microthrombi unless fibrinolysis inhibition (epsilon-aminocaproic acid-EACA) or alpha-adrenergic stimulation (norepinephrine) were provided simultaneously. The mechanism whereby norepinephrine initiated glomerular capillary thrombosis was not related to interference with fibrinolysis nor to potentiation of platelet aggregation and blood coagulation, as indicated by similar consumption of plasminogen and platelets in animals given thrombin alone or combined with norepinephrine, and by the lack of correlation between fibrinogen consumption and the incidence and severity of glomerular thrombosis produced with various dosages (1 to 3 mu/kg/min) of norepinephrine. With norepinephrine, microthrombi were also observed in the adrenals, the spleen and the gastric mucosa. Aspirin prevented the phenomena in the latter two organs, but was inactive or aggravating on thrombogenesis elsewhere. ADP associated with thrombin failed to trigger formation of microthrombi but initiated platelet-rich thrombi in the pulmonary vasculature when associated with norepinephrine. We conclude that unlike thrombin, ADP cannot be held responsible for the microthrombi elicited during experimental intravascular coagulation. Furthermore, the ability of norepinephrine to elicit glomerular thrombosis in thrombin injected rabbits may provide an explanation for requirement of alpha-adrenergic stimulation in the endotoxin-induced generalized Shwartzman reaction.
通过给兔子静脉输注凝血酶或二磷酸腺苷(ADP),研究了血管内凝血过程中产生的微血栓的发病机制。凝血酶以在4小时内使纤维蛋白原消耗70%的剂量(1单位/千克/分钟)给药,除非同时给予纤维蛋白溶解抑制(ε-氨基己酸-EACA)或α-肾上腺素能刺激(去甲肾上腺素),否则不会产生肺外微血栓。去甲肾上腺素引发肾小球毛细血管血栓形成的机制与干扰纤维蛋白溶解或增强血小板聚集和血液凝固无关,这一点可从单独给予凝血酶或同时给予凝血酶和去甲肾上腺素的动物中纤溶酶原和血小板的类似消耗情况,以及不同剂量(1至3微克/千克/分钟)去甲肾上腺素产生的纤维蛋白原消耗与肾小球血栓形成的发生率和严重程度之间缺乏相关性得到证明。使用去甲肾上腺素时,在肾上腺、脾脏和胃黏膜中也观察到了微血栓。阿司匹林可预防后两个器官中的这种现象,但对其他部位的血栓形成无作用或有加重作用。与凝血酶相关的ADP未能触发微血栓形成,但与去甲肾上腺素相关时会在肺血管系统中引发富含血小板的血栓。我们得出结论,与凝血酶不同,ADP不能对实验性血管内凝血过程中引发的微血栓负责。此外,去甲肾上腺素在注射凝血酶的兔子中引发肾小球血栓形成的能力,可能为内毒素诱导的全身性施瓦茨曼反应中对α-肾上腺素能刺激的需求提供一种解释。